pH-Selective Anti-CD138 Antibodies for Tumor Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current approaches for treating and diagnosing multiple myeloma associated with CD138 lack effective targeting and specificity, particularly in acidic tumor microenvironments, leading to reduced therapeutic efficacy and increased toxicity.
Innovation Solution
Development of pH-selective anti-CD138 antibody molecules that exhibit enhanced binding affinity at acidic pH, targeting CD138-expressing tumor cells with improved stability and reduced toxicity, while preferentially binding to membrane-bound CD138 and eliciting effector functions such as ADCC.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional anti-CD138 antibody molecules are used, then they can bind to CD138, but they lack effective targeting in acidic tumor microenvironments and exhibit reduced therapeutic efficacy
Solution Approach 1:
The patent applies parameter changes by modifying the antibody molecule's binding characteristics to be pH-dependent. The antibody exhibits enhanced binding affinity specifically at acidic pH levels (6.0-6.5), which are characteristic of tumor microenvironments, while maintaining reduced binding at physiological pH (7.4). This pH-selective binding parameter change enables the antibody to selectively target tumor cells over normal cells, resolving the contradiction between general binding capability and pH-specific targeting effectiveness.
2Reliability
If conventional anti-CD138 antibody molecules are used, then they can target CD138-expressing cells, but they exhibit increased toxicity and reduced therapeutic efficacy
Solution Approach 1:
The patent applies local quality by creating spatial and environmental selectivity in the antibody's binding behavior. The antibody is designed to exhibit different binding properties in different pH environments - strong binding in acidic tumor microenvironments versus weak binding at physiological pH. This local differentiation of binding quality ensures that the therapeutic effect is concentrated at the tumor site, reducing off-target toxicity while maintaining effective target engagement where needed.
3Ease of manufacture
If conventional anti-CD138 antibody molecules are used, then they can be administered for treatment, but they exhibit increased immunogenicity and decreased stability
Solution Approach 1:
The patent applies parameter changes in the antibody's structural and functional properties to achieve both therapeutic efficacy and enhanced stability. The pH-selective binding mechanism is achieved through specific amino acid residues and structural features that confer both functional selectivity and structural stability. The antibody maintains its binding capability and structural integrity across different physiological conditions, resolving the contradiction between ease of therapeutic application and molecular stability.
Data Source
AI summary
Antibody molecules that specifically bind to CD138 in a tumor microenvironment (e.g., at acidic pH) are disclosed. The antibody molecules can be used to treat, prevent, and/or diagnose disorders, such as multiple myeloma.